Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Error in Figure Key. In the Original Article titled “Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder,” published in the July issue of the Archives (2006;63:741-747), there is an error in the key for Figure 1D. The blue bars represent controls, the yellow bars represent subjects with major depressive disorder, and the green bars represent subjects with bipolar disorder. The figure and correct key are shown below.
D, Regional [18F]FP-TZTP DV (fluorodopa F 18 [3-(3-[3-fluoroproply]thio)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine) in the primary and secondary structures of interest. Analysis of variance (ANOVA) significance at P<.05. ACC indicates anterior cingulate cortex; DCC, dorsal cingulate cortex; PCC, posterior cingulate cortex; *Bipolar disorder (BD)< healthy controls and BD< major depressive disorder (MDD) for t test P<.05; †ANOVA significance at Puncorrected<.05; ‡BD< healthy controls Puncorrected<.05; §BD<MDD Puncorrected<.05.
Error in Figure Key in: Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder. Arch Gen Psychiatry. 2006;63(11):1208. doi:10.1001/archpsyc.63.11.1208
Create a personal account or sign in to: